SEC Tracker
Get the app

Transcode Therapeutics RNAZ

Transcode Therapeutics Q3 FY23: net loss $3.3M; diluted EPS −$24,276.38

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Transcode Therapeutics reported for Q3 FY23, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$3.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$24,276.38No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$0.6510-Q income statement, on EDGAR
  3. Cash and cash equivalents$4.9MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$3.9MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Transcode Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Adial Pharmaceuticals ADIL public float $6M, Jun 30, 2025
  2. AIM ImmunoTech AIM public float $6M, Jun 30, 2025
  3. Vyome Holdings HIND public float $6M, Jun 30, 2025
  4. Biomerica BMRA public float $7M, Nov 28, 2025
  5. Protagenic Therapeutics, Inc.\new PTIX public float $7M, Sep 30, 2025